Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium ulcerans | 1-deoxy-D-xylulose 5-phosphate reductoisomerase | 0.1807 | 0.5 | 0.5 |
Toxoplasma gondii | 1-deoxy-D-xylulose 5-phosphate reductoisomerase, putative | 0.1807 | 0.5 | 0.5 |
Plasmodium vivax | 1-deoxy-D-xylulose 5-phosphate reductoisomerase, putative | 0.1807 | 0.5 | 0.5 |
Mycobacterium leprae | PROBABLE 1-DEOXY-D-XYLULOSE 5-PHOSPHATE REDUCTOISOMERASE DXR (DXP REDUCTOISOMERASE) (1-DEOXYXYLULOSE-5-PHOSPHATE REDUCTOISOMERAS | 0.1807 | 0.5 | 0.5 |
Treponema pallidum | 1-deoxy-D-xylulose 5-phosphate reductoisomerase | 0.1807 | 0.5 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | 1-deoxy-D-xylulose 5-phosphate reductoisomerase | 0.1807 | 0.5 | 0.5 |
Plasmodium falciparum | 1-deoxy-D-xylulose 5-phosphate reductoisomerase | 0.1807 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 5.8 ug ml-1 | Cytotoxic activity of the compound was evaluated against murine Leukemia L1210 cells | ChEMBL. | 9873389 |
IC50 (functional) | = 5.8 ug ml-1 | Cytotoxic activity of the compound was evaluated against murine Leukemia L1210 cells | ChEMBL. | 9873389 |
IC50 (functional) | > 10 ug ml-1 | Cytotoxic activity of the compound was evaluated against Epidermoid Carcinoma KB cells | ChEMBL. | 9873389 |
Median T/C (functional) | = 12 day | Compound was evaluated for antitumor activity in P388/VCR-bearing mice at 200 mg/kg in the presence of vicristine at 0.1 mg/kg | ChEMBL. | 9873389 |
Median T/C (functional) | = 12 day | Compound was evaluated for antitumor activity in P388/VCR-bearing mice at 200 mg/kg in the presence of vicristine at 0.1 mg/kg | ChEMBL. | 9873389 |
Median T/C (functional) | = 15.8 day | Compound was evaluated for antitumor activity in P388/VCR-bearing mice at 200 mg/kg in the presence of vicristine at 0.2 mg/kg | ChEMBL. | 9873389 |
Median T/C (functional) | = 15.8 day | Compound was evaluated for antitumor activity in P388/VCR-bearing mice at 200 mg/kg in the presence of vicristine at 0.2 mg/kg | ChEMBL. | 9873389 |
Range (functional) | = 10 day | Compound was evaluated for antitumor activity in P388/VCR-bearing mice at 200 mg/Kg as in the presence of vicristine at 0.1 mg/kg | ChEMBL. | 9873389 |
Range (functional) | = 10 day | Compound was evaluated for antitumor activity in P388/VCR-bearing mice at 200 mg/Kg as in the presence of vicristine at 0.1 mg/kg | ChEMBL. | 9873389 |
Range (functional) | = 12 day | Compound was evaluated for antitumor activity in P388/VCR-bearing mice at 200 mg/kg in the presence of vicristine at 0.2 mg/kg | ChEMBL. | 9873389 |
Range (functional) | = 12 day | Compound was evaluated for antitumor activity in P388/VCR-bearing mice at 200 mg/kg in the presence of vicristine at 0.2 mg/kg | ChEMBL. | 9873389 |
T/C (functional) | = 105 % | Compound was evaluated for antitumor activity in P388/VCR-bearing mice at 200 mg/kg as in the presence of vicristine at the 0.1 mg/kg | ChEMBL. | 9873389 |
T/C (functional) | = 105 % | Compound was evaluated for antitumor activity in P388/VCR-bearing mice at 200 mg/kg as in the presence of vicristine at the 0.1 mg/kg | ChEMBL. | 9873389 |
T/C (functional) | = 138 % | Compound was evaluated for antitumor activity in P388/VCR-bearing mice at 200 mg/Kg | ChEMBL. | 9873389 |
T/C (functional) | = 138 % | Compound was evaluated for antitumor activity in P388/VCR-bearing mice at 200 mg/Kg | ChEMBL. | 9873389 |
VCR accumulation (functional) | = 276 | Effect of the compound on cellular accumulation of Vincristine(VCR) in multidrug resistant human ovarian cancer 2780AD cells at 1 ug/mL | ChEMBL. | 9873389 |
VCR accumulation (functional) | = 692 | Effect of the compound on cellular accumulation of Vincristine in multidrug resistant human ovarian cancer 2780AD cells at 10 ug/mL | ChEMBL. | 9873389 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Mus musculus | ChEMBL23 | 9873389 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.